Biogen's Long-Term Performance and Uncertain Future
Biogen (BIIB) has struggled with recent financial performance, with only a 2% revenue increase in 2025 and a 7% drop in adjusted earnings per share. Despite long-term outperformance, challenges like biosimilar competition and weak sales in its MS franchise and Spinraza drug are affecting growth. The company's recent regulatory progress may not be enough to drive top-line growth this year.
Tickers: $BIIB
Topics: Alzheimer's Drug Biogen Financial Performance MS Franchise Revenue Growth